Hester Biosciences Ltd
Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.[1]
- Market Cap ₹ 1,868 Cr.
- Current Price ₹ 2,196
- High / Low ₹ 2,684 / 1,239
- Stock P/E 34.8
- Book Value ₹ 453
- Dividend Yield 0.50 %
- ROCE 15.5 %
- ROE 13.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 18.5%
Cons
- Stock is trading at 4.85 times its book value
- The company has delivered a poor sales growth of 6.98% over past five years.
- Company has a low return on equity of 10.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90 | 101 | 123 | 135 | 171 | 169 | 208 | 219 | 254 | 285 | 286 | 292 | 301 | |
| 64 | 67 | 82 | 85 | 103 | 117 | 136 | 159 | 199 | 238 | 235 | 219 | 217 | |
| Operating Profit | 26 | 34 | 41 | 50 | 68 | 53 | 72 | 61 | 55 | 47 | 51 | 73 | 84 |
| OPM % | 29% | 34% | 33% | 37% | 40% | 31% | 35% | 28% | 22% | 17% | 18% | 25% | 28% |
| 3 | 1 | 1 | 2 | 3 | 3 | -4 | 5 | 5 | 4 | 4 | 14 | 15 | |
| Interest | 4 | 4 | 3 | 2 | 4 | 5 | 4 | 2 | 6 | 5 | 5 | 7 | 8 |
| Depreciation | 5 | 6 | 6 | 5 | 8 | 9 | 10 | 10 | 10 | 10 | 9 | 10 | 13 |
| Profit before tax | 19 | 25 | 33 | 44 | 60 | 41 | 55 | 53 | 44 | 37 | 42 | 70 | 79 |
| Tax % | 26% | 23% | 25% | 30% | 27% | 24% | 27% | 26% | 26% | 26% | 24% | 25% | |
| 14 | 19 | 25 | 31 | 44 | 31 | 40 | 40 | 32 | 27 | 32 | 52 | 59 | |
| EPS in Rs | 16.45 | 22.59 | 29.32 | 35.92 | 51.55 | 36.70 | 46.90 | 46.46 | 38.02 | 31.93 | 37.43 | 61.24 | 69.32 |
| Dividend Payout % | 19% | 18% | 18% | 28% | 21% | 18% | 21% | 22% | 21% | 19% | 19% | 18% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 7% |
| 3 Years: | 5% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 2% |
| 3 Years: | 13% |
| TTM: | 72% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -3% |
| 3 Years: | 9% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 12% |
| 3 Years: | 11% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 76 | 92 | 114 | 138 | 171 | 195 | 229 | 260 | 284 | 304 | 331 | 377 |
| 39 | 39 | 39 | 43 | 38 | 48 | 16 | 122 | 164 | 134 | 104 | 75 | |
| 17 | 20 | 17 | 22 | 23 | 26 | 29 | 34 | 89 | 103 | 103 | 97 | |
| Total Liabilities | 140 | 159 | 178 | 210 | 240 | 277 | 282 | 424 | 546 | 550 | 546 | 557 |
| 57 | 62 | 61 | 67 | 101 | 96 | 87 | 84 | 108 | 103 | 105 | 288 | |
| CWIP | 14 | 10 | 21 | 30 | 0 | 1 | 4 | 82 | 149 | 171 | 183 | 9 |
| Investments | 9 | 9 | 9 | 14 | 28 | 41 | 44 | 65 | 65 | 65 | 65 | 64 |
| 61 | 78 | 88 | 99 | 111 | 139 | 148 | 194 | 224 | 210 | 193 | 196 | |
| Total Assets | 140 | 159 | 178 | 210 | 240 | 277 | 282 | 424 | 546 | 550 | 546 | 557 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 19 | 28 | 32 | 36 | 26 | 41 | 16 | 33 | 43 | 64 | 51 | |
| -12 | -6 | -15 | -26 | -25 | -21 | -4 | -111 | -72 | -21 | -19 | -2 | |
| -5 | -12 | -6 | -6 | -20 | -1 | -41 | 95 | 41 | -24 | -46 | -48 | |
| Net Cash Flow | 3 | 1 | 6 | -0 | -9 | 3 | -4 | 0 | 3 | -2 | -1 | 0 |
| Free Cash Flow | 13 | 13 | 12 | 12 | 25 | 18 | 37 | -75 | -39 | 21 | 44 | 34 |
| CFO/OP | 101% | 73% | 84% | 84% | 76% | 71% | 76% | 53% | 75% | 114% | 144% | 89% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 72 | 95 | 79 | 86 | 70 | 96 | 80 | 95 | 118 | 110 | 103 | 115 |
| Inventory Days | 431 | 627 | 356 | 493 | 511 | 754 | 390 | 404 | 362 | 251 | 228 | 267 |
| Days Payable | 68 | 109 | 80 | 100 | 85 | 170 | 96 | 63 | 131 | 109 | 127 | 92 |
| Cash Conversion Cycle | 434 | 614 | 355 | 480 | 496 | 681 | 374 | 436 | 349 | 252 | 204 | 290 |
| Working Capital Days | 55 | 89 | 87 | 94 | 123 | 129 | 182 | 149 | 106 | 130 | 110 | 117 |
| ROCE % | 18% | 22% | 24% | 26% | 31% | 20% | 25% | 17% | 12% | 9% | 11% | 16% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Installed Capacity (Vaccine Doses) Billion doses per annum |
|
||||||||||
| Permanent Employees (Standalone India) Count |
|||||||||||
| Poultry Healthcare Revenue Share (Standalone) % |
|||||||||||
| Total Vaccines in Portfolio Count |
|||||||||||
| Number of Countries Served Count |
|||||||||||
| Number of Distributors in India Count |
|||||||||||
| Poultry Vaccine Market Share in India % |
|||||||||||
| Global PPR Vaccine Market Share % |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Shareholders' Approval For Reclassification From 'Promoter And Promoter Group' Category To 'Public' Category Shareholders
- Shareholders approved reclassification of Ravin Gandhi and Bela Gandhi from promoter to public on 3 September 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
-
Announcement under Regulation 30 (LODR)-Credit Rating
- CARE upgraded Hester Biosciences’ bank ratings to BBB+/Stable and A2 on 27 August 2026.
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
- Postal ballot on reclassifying Ravin Gandhi and Bela Gandhi from promoter to public shareholders.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Aug 2026Transcript REC
-
May 2026Transcript PPT REC
-
Jan 2026Transcript REC
-
Nov 2025Transcript
-
Aug 2025Transcript
-
May 2025Transcript
-
Feb 2025Transcript REC
-
Oct 2024Transcript
-
Aug 2024Transcript
-
May 2024Transcript REC
-
Feb 2024Transcript REC
-
Nov 2023Transcript REC
-
Nov 2023REC
-
Aug 2023Transcript
-
May 2023Transcript
-
Feb 2023Transcript
-
Nov 2022Transcript
-
Aug 2022Transcript
-
Nov 2021Transcript
-
Aug 2021Transcript
-
Jun 2021Transcript
-
Jan 2021Transcript
-
Nov 2020Transcript
-
Aug 2020Transcript
-
Jun 2020Transcript
-
Feb 2020Transcript
-
Nov 2019Transcript
-
Aug 2019Transcript
-
May 2019Transcript
-
Jan 2019Transcript
-
Nov 2018Transcript
-
Oct 2018Transcript
-
Aug 2018Transcript
-
May 2018Transcript
-
Jan 2018Transcript
-
Nov 2017Transcript
-
Jul 2017Transcript
-
May 2017Transcript
-
Jan 2017Transcript
-
Oct 2016Transcript
-
Aug 2016Transcript
-
May 2016Transcript
Business Overview[1]
Hester operates an integrated animal healthcare platform across Poultry Healthcare and Animal Healthcare, offering vaccines, therapeutics, feed supplements, diagnostics, and petcare products. It's portfolio serves poultry farmers, livestock producers, veterinarians, and pet owners through a combination of R&D, manufacturing, quality systems, technical services, and field support.